| Description | Trofinetide (NNZ-2566) is a synthetic analog of the endogenous N-terminus tripeptide. It has been shown to be neuroprotective in animal models of brain injury. |
| In vivo | Trofinetide治疗能够在穿透性弹道样脑损伤（PBBI）后最多7天内抑制受损脑半球中的IL-1β表达。与载体治疗相比，Trofinetide在PBBI后3天内能够抑制由穿透性弹道样脑损伤引起的炎症细胞浸润。所有剂量的Trofinetide均能完全抑制与载体治疗动物相比的NCS延迟发生。Trofinetide治疗显著减少了受伤引起的IL-1β、INF-γ和TNF-α表达的上调。Trofinetide治疗在PBBI后12小时内显著降低了受损半球中IL-6（79%）、E-selectin（81%）、IL-1β（76%）和TNF-α（72%）mRNA水平的升高，最大抑制作用出现在12小时至24小时之间。高剂量的Trofinetide（10和100 mg/kg团块随后连续输注）减轻了永久性中大脑动脉闭塞后2小时以上发生的非惊厥性发作（NCS）[1][2]。 |
| Synonyms | NNZ-2566 |
| molecular weight | 315.32 |
| Molecular formula | C13H21N3O6 |
| CAS | 853400-76-7 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | H2O: 44 mg/mL (139.54 mM) |
| References | 1. Wei HH, et al. NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19. 2. Lu XC, et al. NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats. J Cereb Blood Flow Metab. 2009 Dec;29(12):1924-32. |